Background: The severity of coronary artery disease (CAD) is directly related to the quality of glucose control in diabetic patient. Additionally diabetes is associated with increased mortality following acute myocardial infarction compared to general population. Objectives: To evaluate the association of HbA1c level and severity of CAD, and outcome of non diabetic patient with STEMI In our hospital. Patients and methods: 60 consecutive non diabetic patient with acute ST elevation myocardial infarction were treated with thrombolytic therapy included in the present prospective study. Blood glucose and HbA1c level of all patients were measured within 3 hours of admission. Patient were divided in to 3 groups according to HbA1c level: with cut-off 6.5% as diagnostic criteria of diabetes mellitus according to (American diabetes association) group (1) 6.5%, group (2) 6.5 to 8.5%, group (3) 8.5% and above. In hospital. mortality and morbidities of acute STEMI were compared between groups. Result: The mean age was 63±15 year and mean body mass index was 26. 6±6 kg/m², 24 patients (40%) had history of hypertension, 27 patients (45%) of dyslipidemia, 36 patients (60%) were smoker. We found 45 patients with HbA1c ≤ 6 5%, 5 patients with HbA1c 6.5 -8.5%, 10 patients with HbA1c ≥ 8.5%. There was strong correlation between admission of HbA1c and admission glucose level (P< 0.001). Infarct size as measured by peak creatinin kinase, was not correlated with HbA1c level. Conclusion: HbA1c is an important risk marker in the absence of history of diabetes mellitus in patients with AMI. The optimal management in these patients may contribute in decrease hospital mortality.
INTRODUCTION
Patients with diabetes are at 3-4 times increased risk for cardiovascular mortality compared with nondiabetes (Preis PR etal. 2009 ). In acute coronary syndrome, glucose metabolism is modified and stress hyperglycemia commonly occur secondary to increase catecholamine level (Husband DJ etal. 1983 ). In addition to the higher rate of acute ST-elevation myocardial infarction (STEMI) in diabetes, hyperglycemia is associated with poor prognosis in these patients (Wahab N et al. 2002; Wiviott S et al.2008; Li D et al 2011) . Higher HbA1c level was associated with high cardiovascular disease and death (Selvin E et al. 2010 ). There were some other studies supporting the association between admission serum HbA1c level and increased long-term mortality of non diabetic patients admitted with STEMI and higher rate CAD in these patients (Timmer J et al 2011 , Pia J et al 2013 . We have evaluated the association of admission level of HbA1c with the hospital outcome of non diabetic patient with STEMI.
PATIENTS AND METHODS
All patients of both sexes sustaining acute ST elevation myocardial infarction without diabetes were including in the study. Patients with sepsis, hemoglobinopathies or hypothyroidism tumor, connective tissue diseases, those with sub-acute or chronic MI (longer than 48 hr between first symptom and admission) those with renal failure, hepatic failure, iron deficiency anemia and those with past history of diabetes or used anti diabetic medication were excluded from the study.
Acute myocardial infarction was defined according to the (European Society of Cardiology and American College of Cardiology Criteria). Increased creatine kinase predominantly in the myocardial band fraction and or increased troponin I (creatine kinase 400 U /L or higher and or cardiac troponin I 2 µg / L or higher), ischemic symptoms (mainly constrictive chest pain, lasting longer than 30 min), and or abnormal electrocardiography (ST elevation 1 mm or greater on at least two derivation). MI was defined as acute if the time elapsed between the first symptom and admission was 48 hr or less. only patients who underwent thrombolytic treatment were included in the study. All patients were in cardiac care unit, a brief history was obtained from each patient presenting with acute chest pain including presence of risk factors like smoking and hypertension, dyslipidemia and previous history of ischemic heart disease. Clinical examination was done emphasis on signs of cardiac failure, 12 leads electrocardiography (ECG) was done at cardiac care unit and blood sample were sent to laboratory, blood glucose and HbA1c level of all patients were measured within 3 hr of admission regardless of whether they had been fasting or not and for cardiac enzyme. The fasting lipid profile was determined on the morning following admission and included total cholesterol, high density lipoprotein and triglyceride. All patients were considered for thrombolytic therapy (Injection streptokinase 1.5 million units over one hour) in the absence of all contraindication the management was according to standard treatment protocol. All patients underwent continues ECG monitoring for at least 48 hours on admission to cardiac care unit and daily during hospital stay. Patients were divided into three groups according to the level of HbA1c with cut-off 6.5% as diagnostic criteria of diabetes mellitus according to (American Diabetes Association 2010) for diagnosis and classification of diabetes mellitus. Patient with HbA1c level of 4.5% to 6.4 % group (1), patients with HbA1c level 6.5% to 8.5% group (2) and patients with HbA1c level higher than 8.5 % group 3). None of these patients received glucose, Insulin or potassium infusion therapy during admission. All subjects were hospitalized one week after acute myocardial infarction and hospital records were reviewed at this time. Selective coronary angiography was performed after 1 month. Coronary angiogram was analyzed by two experienced observers who were blinded to the identities and clinical information of the patients. Vessel scores were ranged from zero to three, according to the number of diseased major pericardial vessel with significant stenosis (greater than 50% stenos is of the lumen diameter). Statistical Analysis: Was performed by using SPSS software (Version 12) difference among groups was analyzed by (t-test) and P value 0.05 was considerable significant.
RESULT
Total 60 patients with STEMT were studied. Patients were divided on the bases of admission HbA1c group (1) ≤ 6.5 %; group (2) 6.5-8.5 %; group 3 ≥ 8.5%. The clinical and biological characteristic according to HbA1c are summarized in (table1). The mean age was 63±15 year and mean body mass index was 26. 6±6 kg/m², 24 (40%) had history of hypertension, 27 (45%) of dyslipidemia, 36 (60%) were smoker. We found 45 with HbA1c ≤ 6 .5%; 5 with HbA1c 6.5-8.5%, 10 with HbA1c ≥ 8.5%. There was strong correlation between admission HbA1c and admission glucose level (P< 0.0001). Infarct size as measured by peak creatinin kinase, was not correlated with HbA1c level.
Table1. Clinical and biological characteristics of the study subjects. According to admission HbA1c level

Level of Glycated Hemoglobin
All n=60 Group1 <6.5% n=45 Group2 6. 5 There was significant positive correlation between admission glucose and infarct size measured by peak creatinin kinase level (P<0.0001).
Table2. Clinical outcome of non diabetic patients based on quantities of admission plasma glucose
Admission Glucose Level IQR1 6.9 mmol/ IQR2 7-8. At the end of fourth week coronary angiography performed in remaining 54 patients, revealed that there was significant correlation between HbA1c level at admission and number of disease vessel(P=0.001). Our study shows admission HbA1c level are not associated with high mortality in non diabetic STEMI population treated with streptokinase. In our study high HbA1c in non diabetic patients associated with multivessele involvement of coronary arteries. Similarly, (CakMak, et al 2008) reported a significant correlation between HbA1c level at admission and positive exercise that result after the four week follow up.
Table3. Angiographic data of patients according to HbA1c
Level of Glycosylated Hemoglobin
Hyperglycemia in STEMI patients was strongly associated with increased mortality within 5 days although there is clear correlation between admission glucose and HbA1c level, they appear to represent related but different phenomena. Patients with elevated glucose level have larger MI area.
Recently a prospective cohort study showed that in non diabetic general population, as elevated HbA1c level is a risk factor for the development of cardiovascular events independently of fasting glucose (Selvin E, et suggested that glycosylated hemoglobin is superior to fasting blood glucose in predicting long-term risk of CAD in non diabetes. Similar result are reported by Park and colleagues among non diabetic women (Park et al. 1996) . In a cohort of European men, khaw and colleagues reported that HbA1c correlates linearly to subsequent cardiovascular morbidity, (Khaw et al 2001) . The American Diabetes Association suggests that individual with HbA1c concentration of 5.7-6.4% should be informed of their increased risk for diabetes as well as cardiovascular disease (American Diabetes Association 2010).
CONCLUSION
HbA1c is an important risk marker in the absence of history of diabetes mellitus in patients with AMI. The optimal management in these patients may contribute in decrease hospital mortality. People at high risk for type II diabetes mellitus should receive lifestyle counseling and if needed pharmacological therapy to reduce their risk of developing hyperglycemia and type II diabetes mellitus but especially to prevent or slow the development of CAD. myocardial infarction Am J Cardiol. 2001; 87: 1035-8.
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